• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Evotec SE

    11/15/24 12:30:05 PM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVO alert in real time by email
    6-K 1 evo_6k.htm FORM 6-K evo_6k.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of November, 2024

     

    COMMISSION FILE NUMBER 001-34041

     

    Evotec SE

    (Translation of registrant’s name into English)

     

    Essener Bogen 7

    22419 Hamburg

    Germany

    Tel: +49 40 560810

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐

     

    Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐

     

    Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐

     

     

     

        

    On November 14, 2024, Evotec SE (the “Company”) issued an Ad hoc announcement. A copy of the Ad hoc announcement is attached as Exhibit 99.1 hereto.

     

     
    2

     

     

    EXHIBIT INDEX

     

    Exhibit

     

    Description of Exhibit

    99.1

     

    Comment on media report

     

     
    3

     

     

    SIGNATURE

     

    Pursuant to the requirements of s the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Evotec SE

     

     

    By:

    /s/ Christian Wojczewski

     

    Name: Christian Wojczewski

     

    Title: Chief Executive Officer

     

    Date: November 14, 2024

     

     
    4

     

     

    EXHIBIT INDEX

     

    Exhibit

     

    Description of Exhibit

     

     

     

    99.1

     

    Evotec SE Half-year report dated August 29, 2023

     

     
    5

     

    Get the next $EVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVO

    DatePrice TargetRatingAnalyst
    4/24/2025Sell → Hold
    Deutsche Bank
    10/7/2024Buy → Hold
    Jefferies
    8/8/2024Hold → Sell
    Deutsche Bank
    7/29/2024$15.00 → $6.00Overweight → Equal-Weight
    Morgan Stanley
    7/11/2024Buy → Hold
    Deutsche Bank
    4/12/2024Hold → Buy
    Deutsche Bank
    1/18/2024Sector Perform → Outperform
    RBC Capital Mkts
    6/23/2023$12.00 → $16.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings